21 Result(s)
within
Thomas K. Eigentler
-
Chapter
Therapie bei Lebermetastasen
-
Chapter
Rare Tumors of the Skin and Subcutaneous Tissues
The clinical diagnosis of cutaneous tumors in a child may be a challenge not only due to the rarity of the diseases but also because benign lesions may have alarmingly malignant tumor-like features as well as ...
-
Chapter
Vemurafenib
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF ...
-
Chapter
Targeted Therapies for Melanoma
Targeted therapies for melanoma were developed during the last 5 years. Two main types of targets were addressed: kinase molecules in signaling pathways of melanoma cells were targeted by inhibiting small mole...
-
Article
Increased CCL17 serum levels are associated with improved survival in advanced melanoma
Prognostic factors of melanoma patients with distant metastases remain poorly established. This study aimed to compare the prognostic impact of putative serum biomarkers, namely S100B, YKL-40 or CCL17, in stag...
-
Article
Open AccessOpen-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer a...
-
Article
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
Growing evidence suggests that concurrent loco-regional and systemic treatment modalities may lead to synergistic anti-tumor effects in advanced melanoma. In this retrospective multicenter study, we evaluate t...
-
Article
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study
Treatment of advanced melanoma patients with ipilimumab results in improved survival. However, only about 20% of treated patients experience long-term benefit. Combining treatment of ipilimumab with other drug...
-
Article
Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen
To assess the appearance of gastrointestinal melanoma metastases on CT and PET/CT and evaluate the diagnostic value of CT and PET/CT compared with surgery and histopathology.
-
Article
Open AccessImaging characteristics of cardiac metastases in patients with malignant melanoma
Due to prolonged survival and technical advances in CT imaging, cardiac metastases in patients with malignant melanoma are observed more frequently nowadays. The aim of the present study was to assess the anat...
-
Chapter
Vemurafenib
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF ...
-
Article
Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study
The possibility that tumescence local anaesthesia (TLA) may lead to dissemination of tumour cells in lymph nodes is presently unclear.
-
Article
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only ...
-
Article
Open AccessS100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Immunotherapy with PD-1 antibodies has greatly increased prognosis of patients with advanced melanoma. Identifying biomarkers that predict overall survival (OS) and response to immunotherapy is important.
-
Article
Open AccessCombined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.
-
Article
Open AccessSerum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Despite impressive response rates, most patients with advanced melanoma ultimately progress following therapy with B-Raf proto-oncogene (BRAF) inhibitors (BRAFi). Therefore, frequent radiologic assessments are...
-
Article
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Hepatic immune-related adverse events (irAE) including elevated liver function tests (transaminases) occur in 1.4–22.3% of melanoma patients receiving immune checkpoint inhibitors (ICPI) and constitute a poten...
-
Article
Open AccessNoninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients
As cancer cachexia (CC) is associated with cancer progression, early identification would be beneficial. The aim of this study was to establish a workflow for automated MRI-based segmentation of visceral (VAT)...
-
Chapter
Skin Carcinoma
Squamous cell carcinoma of the skin is very uncommon in children and adolescent. This tumor is a malignant locally destructive epithelial malignancy which rarely metastasizes in non-immunosuppressed patients. ...
-
Chapter
Cutaneous Melanoma
Cutaneous melanoma is rare in children, but its incidence increases in adolescents. The pathogenesis of melanoma is multifactorial, making prevention important in its clinical history. The clinical management ...
